{"id":"W3168935284","doi":"10.1038/s41586-021-03642-9","title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","year":2021,"lang":"en","type":"article","venue":"Nature","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":604,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Hazard ratio; Medicine; Atezolizumab; Internal medicine; Confidence interval; Oncology; Population; Clinical endpoint; Adjuvant; Bladder cancer; Adjuvant therapy; Biomarker; Immunotherapy; Cancer; Randomized controlled trial; Nivolumab; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006544099,0.0002012095,0.0004110971,0.0005235144,0.0003430808,0.001080143,0.0002758127,0.0006939182,0.002279897],"category_scores_gemma":[0.002404736,0.0001565496,0.0001974426,0.0004804193,0.0004637091,0.0004809352,0.0002606547,0.0008672597,0.000547335],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001001301,"about_ca_system_score_gemma":0.001218786,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001963647,"about_ca_topic_score_gemma":0.004388668,"domain_scores_codex":[0.9998022,0.00005728352,0.00002562166,0.0000276127,0.00005147939,0.00003587071],"domain_scores_gemma":[0.9992342,0.0003451909,0.0001391968,0.0000420177,0.0001328817,0.0001063996],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.004317484,0.0004130299,0.06983408,0.001313177,0.000123167,0.002978807,0.0002311129,0.004174349,0.05058932,0.00763849,0.02723912,0.8311477],"study_design_scores_gemma":[0.001506135,0.005780338,0.1886498,0.002805741,0.001081271,0.02570509,0.0007647836,0.02123804,0.1177498,0.03000845,0.6045825,0.0001281701],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4534874,0.3899547,0.01457859,0.04224135,0.005441547,0.000327746,0.0008385776,0.0005148262,0.09261518],"genre_scores_gemma":[0.923421,0.04922845,0.01147782,0.005583232,0.00241437,0.00008472298,0.0004794358,0.00009053521,0.007220414],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002279897,"threshold_uncertainty_score":0.00762707,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0179659904279273,"score_gpt":0.294829534070764,"score_spread":0.2768635436428367,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}